Nasdaq Thrx News Today

Denali Advisors LLC boosted its stake in shares of Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Free Report) by 675.2% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 127,900 shares of the company’s stock after purchasing an additional 111,400 shares during the period. Denali Advisors LLC owned approximately 0.29% […]

Theseus Pharmaceuticals (NASDAQ:THRX – Get Free Report) and MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends. Insider and Institutional Ownership 91.1% of Theseus Pharmaceuticals […]

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Get Free Report)’s share price traded down 0.4% during trading on Tuesday . The stock traded as low as $2.27 and last traded at $2.30. 105,762 shares changed hands during trading, a decline of 68% from the average session volume of 335,687 shares. The stock had previously closed at $2.31. […]

Wedbush reiterated their outperform rating on shares of Theseus Pharmaceuticals (NASDAQ:THRX – Free Report) in a research report sent to investors on Thursday, RTT News reports. The brokerage currently has a $7.00 target price on the stock. Wedbush also issued estimates for Theseus Pharmaceuticals’ Q1 2024 earnings at ($0.33) EPS, Q2 2024 earnings at ($0.35) […]

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Get Free Report) Director Carl L. Gordon bought 479,932 shares of the company’s stock in a transaction on Monday, July 17th. The shares were bought at an average price of $3.05 per share, for a total transaction of $1,463,792.60. Following the completion of the acquisition, the director now directly owns […]

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Get Free Report) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 1,440,000 shares, an increase of 25.2% from the June 15th total of 1,150,000 shares. Currently, 9.5% of the company’s stock are short sold. Based on an […]

Shares of Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Get Free Report) rose 0.7% on Tuesday . The stock traded as high as $10.26 and last traded at $10.04. Approximately 78,289 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 214,724 shares. The stock had previously closed at $9.97. Wall […]

Theseus Pharmaceuticals (NASDAQ:THRX – Get Free Report) had its target price lowered by research analysts at HC Wainwright from $22.00 to $9.00 in a report released on Friday, FlyOnTheWall reports. HC Wainwright’s target price indicates a potential downside of 5.46% from the stock’s current price. Theseus Pharmaceuticals Stock Down 3.7 % NASDAQ THRX opened at […]

Theseus Pharmaceuticals (NASDAQ:THRX – Get Free Report) had its price objective dropped by stock analysts at HC Wainwright from $22.00 to $9.00 in a research report issued to clients and investors on Friday, FlyOnTheWall reports. HC Wainwright’s target price suggests a potential downside of 5.46% from the company’s previous close. Theseus Pharmaceuticals Trading Down 3.7 […]

Opaleye Management Inc. grew its stake in shares of Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Get Rating) by 142.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 535,000 shares of the company’s stock after buying an additional 314,350 shares during the period. Opaleye Management Inc.’s holdings in Theseus […]